[1] Denning DW,Pleuvry A,Cole DC.Global burden of chronic pulmonary aspergillosis complicating sarcoidosis[J].Eur Respir J,2013,41(3):621-626.
[2] 徐媛,陈敏,廖万清.中国侵袭性曲霉菌病流行病学现状[J].中国真菌学杂志,2018,13(1):57-60.
[3] Denning DW,Cadranel J,Beigelman-Aubry C,et al.Chronic pulmonary aspergillosis:rationale and clinical guidelines for diagnosis and management[J].Eur Respir J,2016,47(1):45-68.
[4] Patterson TF,Thompson GR,Denning DW,et al.Practice guidelines for the diagnosis and management of aspergillosis:2016 Update by the Infectious Diseases Society of America[J].Clin Infect Dis,2016,63(4):e1-e60.
[5] Al-Shair K,Muldoon EG,Morris J,et al.Characterisation of fatigue and its substantial impact on health status in a large cohort of patients with chronic pulmonary aspergillosis(CPA)[J].Respir Med,2016,114(5):117-122.
[6] Maghrabi F,Denning DW.The management of chronic pulmonary aspergillosis:The UK National Aspergillosis Centre Approach[J].Curr Fungal Infect Rep,2017,11(4):242-251.
[7] Diamond RD,Haudenschild CC,Erickson NF. Monocyte-mediated damage to Rhizopus oryzae hyphae in vitro[J].Infect Immun,1982,38(1):292-297.
[8] Patterson KC,Strek ME.Diagnosis and treatment of pulmonary aspergillosis syndromes[J].Chest,2014, 146(5):1358-1368.
[9] Imburgia C,Buscemi C,Corrao S. Pulmonary infiltrate with characteristic "reversed halo" and "air crescent" signs[J].Eur J Intern Med,2017,41(6):e3-e4.
[10] Farid S,Mohamed S,Devbhandari M,et al.Results of surgery for chronic pulmonary aspergillosis,optimal antifungal therapy and proposed high risk factors for recurrence-a National Centre's experience[J].J Cardiothorac Surg,2013,8(5):180-186.
[11] Al-Shair K,Atherton GT,Harris C,et al.Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis:a longitudinal analysis[J].Clin Infect Dis,2013,57(6):828-835.
[12] Kono Y,Tsushima K,Yamaguchi K,et al.The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosis[J].Respir Med,2013,107(7):1094-1100. |